Future Oncol. 2012;8(9):1135-1147.

Every woman has a one in 87 chance of getting ovarian cancer in her lifetime, and one in 130 will die from it. The symptoms ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable futur ...

GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...

with a high risk of recurrence. Furthermore, medical therapy of ovarian cancer impacts quality of life owing to the common occurrence of chemotherapy side effects, such as alopecia, neurotoxicity ...

LONDON, UK I, 2024 I GSK plc (LSE/NYSE: GSK) today announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula ...

But what if they could prevent the spread of cancer altogether? Well, that’s precisely what OvarianVax, the world’s first ovarian cancer prevention vaccine, strives to do. Researchers at the ...

GSK has announced positive results from a phase III trial of its ovarian cancer treatment, which met its primary endpoint of ...

including a preliminary dose-finding combination study of Zejula and Keytruda with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer.

GSK's combined drugs Jemperli and Zejula met its primary goal of progression-free survival in patients with first line advanced ovarian cancer in a late-stage trial.